Lyell Immunopharma (NASDAQ:LYEL) PT Lowered to $6.00

Lyell Immunopharma (NASDAQ:LYEL) had its target price lowered by equities researchers at Bank of America from $9.00 to $6.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Bank of America‘s target price would suggest a potential upside of 313.79% from the stock’s current price.

Separately, HC Wainwright restated a “neutral” rating and set a $1.00 price target (down from $6.00) on shares of Lyell Immunopharma in a research note on Thursday.

Lyell Immunopharma Stock Performance

NASDAQ LYEL opened at $1.45 on Thursday. Lyell Immunopharma has a twelve month low of $1.18 and a twelve month high of $3.41. The stock has a market capitalization of $369.66 million, a PE ratio of -1.61 and a beta of -0.40. The stock has a 50-day simple moving average of $2.39 and a 200 day simple moving average of $2.24.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings data on Monday, May 6th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.04). Lyell Immunopharma had a negative return on equity of 33.92% and a negative net margin of 335,794.09%. As a group, equities research analysts forecast that Lyell Immunopharma will post -0.85 EPS for the current fiscal year.

Hedge Funds Weigh In On Lyell Immunopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. ProShare Advisors LLC grew its stake in shares of Lyell Immunopharma by 9.3% in the 1st quarter. ProShare Advisors LLC now owns 48,986 shares of the company’s stock valued at $109,000 after purchasing an additional 4,170 shares during the period. Profund Advisors LLC grew its stake in shares of Lyell Immunopharma by 20.0% in the 3rd quarter. Profund Advisors LLC now owns 73,442 shares of the company’s stock valued at $108,000 after purchasing an additional 12,225 shares during the period. Public Employees Retirement System of Ohio grew its stake in shares of Lyell Immunopharma by 109.7% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 27,203 shares of the company’s stock valued at $40,000 after purchasing an additional 14,229 shares during the period. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Lyell Immunopharma in the 4th quarter valued at approximately $31,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Lyell Immunopharma by 67.7% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 48,855 shares of the company’s stock valued at $109,000 after purchasing an additional 19,718 shares during the period. 66.05% of the stock is currently owned by institutional investors.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.